Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04768855 · ClinicalTrials.gov registry record · Phase 1
A Study of LY3540378 in Healthy Participants
A Phase 1 study of Healthy, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 134
- Enrollment target
- 2
- Study locations
NCT04768855 is a Phase 1 study of Healthy that has completed, run by Eli Lilly and Company. The registered enrollment target is 134 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (79% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT04768855, a Phase 1 study of Healthy, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 134 participants
- Enrollment target
- 2
- Study locations
Study Summary
The main purpose of this study is to evaluate the safety and tolerability of the study drug known as LY3540378 in healthy participants following single and multiple doses (Parts A and B) and multiple doses in Japanese (Part C) and Chinese (Part D) healthy participants. Blood tests will be performed to check how much LY3540378 gets into the bloodstream and how long it takes the body to eliminate it. This is a 4-part study and may last up to 70, 113, 113 and 113 days for each participant in Parts A, B, C, and D respectively.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG LY3540378
Study Locations (2)
California
- Anaheim Clinical Trials, LLC - Anaheim
Other
- Lilly Centre for Clinical Pharmacology - Singapore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 134 participants |
| Start Date | 2021-03-17 |
| Est. Completion | 2022-05-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04768855
The ClinicalTrials.gov registry entry for NCT04768855 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 134 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (79% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04768855 reports 2 study locations spanning 2 distinct geographic areas - top geographies include California, Other.
Frequently Asked Questions
What is clinical trial NCT04768855 about?
NCT04768855 is a clinical study titled "A Study of LY3540378 in Healthy Participants". The main purpose of this study is to evaluate the safety and tolerability of the study drug known as LY3540378 in healthy participants following single and multiple doses (Parts A and B) and multiple doses in Japanese (Part C) and Chinese (Part D) healthy participants. Blood tests will be performed ...
What is the current status of trial NCT04768855?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 134 participants. The study started on 2021-03-17. Estimated completion is 2022-05-30.
What conditions does trial NCT04768855 study?
This clinical trial studies the following conditions: Healthy.
What interventions are being tested in trial NCT04768855?
The interventions under investigation include: Placebo (DRUG), LY3540378 (DRUG).
Who is sponsoring clinical trial NCT04768855?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04768855 being conducted?
This trial has 2 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
RECRUITING · Phase 1
-
A Study of LY3867070 in Healthy Participants
RECRUITING · Phase 1
-
A Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of AZD1613 in Healthy Participants.
RECRUITING · Phase 1
-
Evaluate the Pharmacokinetics, Safety, and Tolerability of NSHO-101 in Healthy Participants
RECRUITING · Phase 1
-
Comparison of the Short-Term Effect of Dietary Carbohydrate Restriction Versus Exogenous Ketone Supplementation on Myocardial Glucose Suppression and Timing to Achieve a State of Ketosis Using FDG PET/CT Serial Imaging
RECRUITING · Phase 1
-
A Study of V118E in Healthy Participants (V118E-003)
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.